News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,116 Results
Type
Article (14984)
Company Profile (299)
Press Release (266827)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79910)
Career Advice (182)
Deals (13341)
Drug Delivery (39)
Drug Development (50721)
Employer Resources (31)
FDA (5847)
Job Trends (5190)
News (145211)
Policy (10091)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (927)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21783)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6041)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4580)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (164)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43674)
Collaboration (1149)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1113)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1380)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31656)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51717)
Executive appointments (623)
FDA (7596)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1152)
Grass and pollen (3)
Guidances (167)
Healthcare (6623)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1217)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (23)
IPO (7346)
IRA (12)
Job creations (870)
Job search strategy (141)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1402)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2678)
Medtech (2687)
Mergers & acquisitions (6618)
Metabolic disorders (726)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2050)
Non-profit (880)
Now hiring (30)
Obesity (331)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26676)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15474)
Phase 2 (20292)
Phase 3 (12822)
Pipeline (3241)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (647)
Real estate (1449)
Recruiting (12)
Regulatory (9904)
Reports (19)
Research institute (971)
Resumes & cover letters (21)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (4)
Last 7 days (345)
Last 30 days (1279)
Last 365 days (17836)
2026 (1653)
2025 (18105)
2024 (20557)
2023 (22431)
2022 (26842)
2021 (27875)
2020 (23391)
2019 (16276)
2018 (11774)
2017 (13764)
2016 (11874)
2015 (14380)
2014 (10423)
2013 (7516)
2012 (7552)
2011 (7631)
2010 (7444)
Location
Africa (158)
Alabama (65)
Alaska (3)
Arizona (71)
Arkansas (5)
Asia (18269)
Australia (3114)
California (7077)
Canada (1838)
China (773)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39202)
Florida (902)
Georgia (210)
Hawaii (2)
Idaho (17)
Illinois (396)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (248)
Mississippi (3)
Missouri (33)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1646)
New Mexico (13)
New York (1760)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1278)
Puerto Rico (9)
Rhode Island (26)
South America (218)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (906)
United States (23334)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
282,116 Results for "relay therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
·
1 min read
Press Releases
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November 2025
November 3, 2025
·
1 min read
Press Releases
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
February 3, 2026
·
8 min read
Press Releases
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
November 6, 2025
·
10 min read
Press Releases
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
October 31, 2025
·
1 min read
Press Releases
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September 2025
August 29, 2025
·
1 min read
Press Releases
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
December 12, 2025
·
8 min read
Press Releases
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
August 8, 2025
·
9 min read
Layoffs
Relay Therapeutics to Lay Off 10% of Workforce
Relay Therapeutics is cutting its workforce to help streamline its research organization as it looks to complete its first large-scale, pivotal clinical trial.
October 4, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
June 12, 2025
·
5 min read
1 of 28,212
Next